-- Studies performed at the University of Geneva in 2018 for the Company’s BARD1 autoantibody (AAb) test for detection of ovarian cancer published in international peer-reviewed journal Genes
-- The research-stage BARD1 AAb assay showed a predicted accuracy of 0.96 with 86% sensitivity at 95% specificity cut-off for detection of ovarian cancer in asymptomatic women compared to healthy controls
-- Similar high predicted accuracy of 0.97 for ovarian cancer was shown in high-risk women with hereditary breast and ovarian cancer syndrome (HBOC)
-- The AAb-based test is one of the approaches that BARD1 is developing for ovarian cancer to enable earlier detection, save women’s lives and avoid unnecessary surgery
For more information, download the attached PDF.
Download this document
